Detection of COPD in a high-risk population: Should the diagnostic work-up include bronchodilator reversibility testing?

International Journal of COPD

Volumn 10, Issue , 2015, Pages 407-414

  Kjeldgaard, Peter ^a   Dahl, Ronald ^b   Løkke, Anders ^c   Ulrik, Charlotte Suppli ^a,d  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chronic obstructive pulmonary disease; Diagnosis; Reversibility; Screening; Spirometry

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADULT; AIRWAY OBSTRUCTION; ALGORITHM; ARTICLE; ASSESSMENT OF HUMANS; ASTHMA; BODY MASS; BRONCHODILATOR REVERSIBILITY TESTING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DIAGNOSTIC SCREENING ALGORITHM; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG RESPONSE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RESEARCH COUNCIL SCALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PREVALENCE; SMOKING; SPIROMETRY; AGED; CLINICAL PATHWAY; DENMARK; DRUG EFFECTS; EVALUATION STUDY; GENERAL PRACTICE; INHALATIONAL DRUG ADMINISTRATION; LUNG; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; VERY ELDERLY; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CRITICAL PATHWAYS; DENMARK; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL PRACTICE; HUMANS; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SPIROMETRY; VITAL CAPACITY;

EID: 84923353061     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S76047     Document Type: Article

References (35)

1. European Respiratory Society. European Lung White Book. 2013. Available from: www.erswhitebook.org. Accessed January 12, 2015.
2. Lokke A, Ulrik CS, Dahl R, et al. Detection of previously undiagnosed cases of COPD in a high-risk population identified in general practice. COPD. 2012;9(5):458–465.
3. Tinkelman DG, Price D, Nordyke RJ, Halbert RJ. COPD screening efforts in primary care: what is the yield? Prim Care Respir J. 2007; 16(1):41–48.
4. Zieliñski J, Bednarek M; Know the Age of Your Lung Study Group. Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001;119(3):731–736.
5. 1 decline in COPD patients according to severity stages. Am J Respir Crit Care Med. 2008;177:A401.
6. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–1178.
7. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
8. Thorn J, Tilling B, Lisspers K, Jörgensen L, Stenling A, Stratelis G. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis. Prim Care Respir J. 2012;21(2):159–166.
9. Frith P, Crockett A, Beilby J. Simplified COPD screening: validation of the PiKo-6(R) in primary care. Prim Care Respir J. 2011;20(2): 190–198.
10. Dirven JA, Muris JW, van Schayck CP. COPD screening in general practice using a telephone questionnaire. COPD. 2010;7(5):352–359.
11. Canals-Borrajo G, Martínez-Andión B, Cigüenza-Fuster ML. Spirometry for detection of undiagnosed chronic obstructive pulmonary disease in primary care. Eur J Gen Pract. 2010;16(4):215–221.
12. Stratelis, G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Br J Gen Pract. 2004;54(500):201–206.
13. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586.
14. Madsen F, Maltbæk N, Mortensen J, Pedersen OF. Lungefunktionsstandard. Danish Society of Respiratory Medicine, 2007.
15. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.
16. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of COPD. 2014. Available from: www.goldcopd.com. Accessed January 12, 2015.
17. Danish Society of Respiratory Medicine. [Guidelines for diagnosis of asthma 2010]. Available from: www.lungemedicin.dk. Accessed January 12, 2015.
18. Maltais, F, Dennis N, Chan CK. Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. COPD. 2013;10(1):79–103.
19. Román-Rodríguez M. Early treatment benefits in chronic obstructive pulmonary disease. Hot Topics in Respiratory Medicine. 2010;14:19–26.
20. Johansson G, Lindberg A, Romberg K, Nordström L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J. 2008;17(3):169–175.
21. Laniado-Laborin R, Rendón A, Bauerle O. Chronic obstructive pulmonary disease case finding in Mexico in an at-risk population. Int J Tuberc Lung Dis. 2011;15(6):818–823.
22. Hill K, Hodder R, Blouin M, Heels-Ansdell D, Guyatt G, Goldstein R. Identifying adults at risk of COPD who need confirmatory spirometry in primary care: do symptom based questions help? Can Fam Physician. 2011;57(2):e51–e57.
23. Jordan RE, Lam KB, Cheng KK, et al. Case finding for chronic obstructive pulmonary disease: a model for optimising a targeted approach. Thorax. 2010;65(6):492-498.
24. Castillo D, Guayta R, Giner J, et al. COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study. Respir Med. 2009;103(6):839–845.
25. Vandevoorde J, Verbanck S, Gijssels L, et al. Early detection of COPD: a case finding study in general practice. Respir Med. 2007;101(3): 525–530.
26. Ulrik CS, Løkke A, Dahl R, et al. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis. 2011;6:123–127.
27. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8(8): 1398–1420.
28. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31(4):742–750.
29. Reid DW, Soltani A, Johns DP, et al. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Intern Med J. 2003;33(12):572–577.
30. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701–708.
31. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–664.
32. Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011;12:6.
33. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2014. Available from: www.ginasthma.org. Accessed January 13, 2014.
34. Hanania NA, Celli BR, Donohue JF, Martin UJ. Bronchodilator reversibility in COPD. Chest. 2011;140(4):1055–1063.
35. Anthonisen NR, Lindgren PG, Tashkin DP, et al. Bronchodilator response in the Lung Health Study over 11 yrs. Eur Respir J. 2005;26(1):45–51.